TCGA-79-5596-01A-31R-1949-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- G2M_CHECKPOINT+0.410
- E2F_TARGETS+0.390
- MYC_TARGETS_V1+0.370
- WNT_BETA_CATENIN_SIGNALING+0.340
- HEDGEHOG_SIGNALING+0.290
- MITOTIC_SPINDLE+0.280
- OXIDATIVE_PHOSPHORYLATION+0.260
- P53_PATHWAY+0.260
- MTORC1_SIGNALING+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_GAMMA_RESPONSE-0.510
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.380
- PROTEIN_SECRETION-0.380
- COMPLEMENT-0.320
- KRAS_SIGNALING_UP-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- NOTCH_SIGNALING-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8153-01A-11R-2403-07 | — | cohortSQ2 | 0.901 |
| 2 | C3N-02434 | — | cohortSQ2 | 0.892 |
| 3 | C3N-04155 | — | cohortSQ2 | 0.884 |
| 4 | TCGA-58-8391-01A-11R-2326-07 | — | cohortSQ2 | 0.880 |
| 5 | TCGA-85-8052-01A-11R-2247-07 | — | cohortSQ2 | 0.872 |
| 6 | MDT-AP-0513 | Med | Medulloblastoma | 0.866 |
| 7 | TCGA-58-8392-01A-11R-2326-07 | — | cohortSQ2 | 0.865 |
| 8 | TCGA-56-7823-01B-11R-2247-07 | — | cohortSQ2 | 0.864 |
| 9 | R25 | — | — | 0.864 |
| 10 | TCGA-68-7755-01A-11R-2125-07 | — | cohortSQ2 | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |